Storia in 2 fonti

iDexis taking legal advice after court rules against it in weight-loss jab case

Novo Nordisk welcomes ruling, saying it clarifies compounding rules

Raccontata daafrica.businessinsider.combusinessday.co.za

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

africa.businessinsider.com3 g fa

South African court blocks pharmacy accused of selling unapproved Ozempic-style weight-loss drugs

A South African court has ordered pharmacy group iDexis to halt sales of semaglutide-based medicines in a legal victory for Novo Nordisk, maker of Ozempic and Wegovy

Leggi questa versione → originale

businessday.co.za3 g fa

Novo Nordisk wins interim order barring SA rival from selling Ozempic copies

Novo Nordisk won a court order blocking iDexis from selling unregistered semaglutide; iDexis produced 84,500 monthly units, exceeding combined Novo sales. The ruling tightens IP protection and supply-chain transparency for pharma manufacturing, raising compliance standards in emerging markets.

Leggi questa versione → originale

Timeline cronologica

1. lunedì 22 giugno 2026·africa.businessinsider.com
   

   South African court blocks pharmacy accused of selling unapproved Ozempic-style weight-loss drugs

   A South African court has ordered pharmacy group iDexis to halt sales of semaglutide-based medicines in a legal victory for Novo Nordisk, maker of Ozempic and Wegovy

2. lunedì 22 giugno 2026·businessday.co.za
   

   Novo Nordisk wins interim order barring SA rival from selling Ozempic copies

   Interim order bars iDexis from selling weight-loss medicines containing semaglutide, the key ingredient in Ozempic and Wegovy

3. giovedì 25 giugno 2026·businessday.co.za
   

   iDexis taking legal advice after court rules against it in weight-loss jab case

   Novo Nordisk welcomes ruling, saying it clarifies compounding rules